{"prompt": "['Charit\u00e9 Universit\u00e4tsmedizin Berlin', 'Prof. Dr. med. Dominik Modest', 'FIRE-9 PORT', '28-Sep-2021', 'EudraCT no. 2020-006144-18', 'Protocol Version 3.0', '2', 'Trial Design', '2.1 Trial Design', 'This is an open-label, randomized, controlled, multicenter, phase III study with two parallel', 'arms. Patients with metastatic colorectal cancer after definite interventional therapy of all', 'lesions are randomized in a 2:1 fashion (favoring active therapy) to investigate the efficacy,', 'patient reported quality of life and safety of mFOLFOXIRI/mFOLFOX-6 as additive treatment', '(Arm A) versus active follow-up/surveillance (Arm B).', 'Figure 1: Illustration of Trial Design', 'Post-Resection Therapy in patients with metastatic colorectal cancer', 'PART', 'Fire-9 I AIO 0418', 'Study design', 'Primary endpoint: progression-free survival (PFS)', 'mFOLFOXIRI q2w (up to 6 months)', 'Relapse', 'adjusted treatment duration up to a total of 6 months', 'CRC. ECOG 0-1', 'oxaliplatin-based therapy including pre-operative regimens', 'Structured', 'specimen', '2/3', 'FOLFOX6 q2w (up to 6 months)', 'Follow-up', 'After definitive', 'adjusted treatment duration up to a total of 6 months', 'treatment of', 'oxaliplatin-based therapy including pre-operative regimens', 'any metastases', '(incl. surgery. stereotactic', 'Relapse', 'radiation, ablative techniques)', 'Structured Follow-up', 'specimen', 'Stratification', '1 number of treated metastases', '(>2 vs. 1-2)', '2. pretreatment with systemic therapy', 'for metastatic colorectal cancer', 'yes vs. no', '3. choice of potential therapy in the trial', '(fit for vs. fit for FOLFOX)', '4. presence of least one bad prognostic', 'factor (peritoneal metastases resected/', 'Biomarkers', 'Biomarkers', 'known BRAF mutation/ synchronous', 'metastases defined as evidence of', '- Tumor samples', '- Tumor samples', 'metastases <12 months vs. >12 months', 'after first diagnosis) vs. no bad prognostic', '- Blood samples', '- Blood samples', 'factor)', 'Confidential', 'Page 20 of 79']['Charit\u00e9 Universit\u00e4tsmedizin Berlin', 'Prof. Dr. med. Dominik Modest', 'FIRE-9 PORT', '28-Sep-2021', 'EudraCT no. 2020-006144-18', 'Protocol Version 3.0', '2.2 Trial Scheme', 'The trial will consist of both a clinical and translational part. During the study, re-assessments', '(radiologic assessment, blood and QoL) will be conducted for all trial subject of the trial every', '3 months. Tumor biopsies will be collected at screening (baseline sample) and in case of', 'relapse of disease if a new tumor sample is obtained.', 'The objective of the re-assessments is detection of relapse either radiologically or within the', 'translational material (blood samples with ctDNA dynamics and tumor - if available from', 'relapses). CT scans of thorax/abdomen and/or MRI scans will be performed every 3 months', 'within the 2 years after randomization. After the first two relapse-free years, intervals should', 'be stretched to 6 months in the third and following years after study start. Structured follow-up', 'for up to 60 months after randomization should be maintained for both arms.', 'Patients in Arm A receive additive study drug intervention (mFOLFOXIRI or mFOLFOX-6) for', 'up to six months (12 cycles) after randomization with additional clinical and safety', 'assessments as specified in Section 2.3.', 'Allocation to study treatment FOLFOX/FOLFOXIRI for patients in Arm A is stratified and done', \"by investigator's choice. The decision considers but is not limited to factors as age,\", 'performance status, previous therapy, and side effects of previous therapy. Since obligatory', 'criteria cannot be made treatment allocation will not be regulated by the protocol but', 'stratification will avoid that treatment allocation promotes any bias.', 'Figure 2: Study Flow Chart', 'Post-Resection Therapy in patients with metastatic colorectal cancer', 'PART', 'Fire-91AIO 0418', 'PFS (primary endpoint)', '24 months after randomization', 'Week 3-10', '3 months', '6 months', 'Follow-up for', 'up to 60 months', 'Screening and', 'after random.', 'inclusion', 'Resection/', 'Randomization', 'Relapse', 'Ablation/ of mCRC', 'or', 'Radiation', 'Death', 'Study intervention', '(treatment vs. structured follow-up)', 'Radiologic', 'Radiologic', 'Radiologic', 'In cases of realapse', 'and available bio-material:', 'assessment', 'assessment', 'assessment', 'Assessment of', 'Assessment of', 'Assessment of', 'Assessment of', '- Tumor', 'Tumor', 'Blood', '- Blood', '- Blood', 'Blood', '- EQ5D5L', 'EQ5D5L', '- EQ5D5L', '- EQ5D5L', 'Confidential', 'Page 21 of 79']\n\n###\n\n", "completion": "END"}